Advances in Nasal Biopharmaceutics to Support Product Development and Therapeutic Needs

Ben Forbes, Lucy Goodacre, Alison Lansley, Andrew Martin, Helen Palmer, Claire Patterson, Chris Roe, Regina Scherließ

Research output: Contribution to journalArticlepeer-review

Abstract

Background/Objectives: Nasal biopharmaceutics is the scientific understanding of product and patient factors that determine the rate and extent of drug exposure following nasal administration. The authors considered whether current biopharmaceutics tools are fit for the current and future needs of nasal product development and regulation. Methods: The limitations of current methods were critically assessed, unmet needs were highlighted, and key questions were posed to guide future directions in biopharmaceutics research. Results: The emergence of physiologically based biopharmaceutics models for nasal delivery has the potential to drive the scientific understanding of nasal delivery. Simulations can guide formulation and device development, inform dose selection and generate mechanistic insights. Developments in modeling need to be complemented by advances in experimental systems, including the use of realistic or idealized nasal casts to estimate the regional deposition of nasal sprays and refined in vitro cell culture models to study nasal drug absorption and the influence of mucus. Similarly, improvements are needed to address the practicalities of using animals in non-clinical studies of nasal drug delivery, and greater clinical use of gamma scintigraphy/magnetic resonance imaging is recommended to measure the delivery and nasal retention of different formulations in humans. Conclusions: Nasal drug delivery is a rapidly growing field and requires advances in nasal biopharmaceutics to support product innovation. Key needs are (i) validated clinically relevant critical product attributes for product performance and (ii) established links between how patients administer the product and where in the nose it deposits and dissolves in order to act or be absorbed, leading to its desired clinical effect.
Original languageEnglish
Article number1321
Number of pages21
JournalPharmaceutics
Volume17
Issue number10
DOIs
Publication statusPublished - 11 Oct 2025

Bibliographical note

Publisher Copyright:
© 2025 by the authors.

Keywords

  • nasal drug products
  • PBBM
  • nasal deposition
  • cell and mucus models
  • preclinical development
  • gamma scintigraphy

Fingerprint

Dive into the research topics of 'Advances in Nasal Biopharmaceutics to Support Product Development and Therapeutic Needs'. Together they form a unique fingerprint.

Cite this